The body of evidence that supports the use of angiotensin-converting enzyme (ACE) inhibitors in an ever-wider spectrum of clinical conditions grows steadily greater. These drugs are now widely employed by general physicians, cardiologists, gerentologists, diabetologists and of course by nephrologists. Indeed, for the treatment of hypertension ACE inhibitors are now prescribed more frequently than beta-blockers in the United States. 1 Therapy with an ACE inhibitor is established for reducing excessive blood pressure, reducing mortality in patients with congestive heart failure (CHF), preventing the development of CHF in patients with asymptomatic left ventricular (LV) dysfunction, and preventing death and CHF when initiated early after the onset of acute myocardial infarction (MI). Although these benefits have been attributed largely to haemodynamic mechanisms, recent preclinical and clinical evidence reveal ACE inhibition as potent in preventing ischaemic events and in blocking an array of ischaemic processes, including atherogenesis. 2 Yet further benefits from ACE inhibition are seen in diabetic retinopathy 3 and are suggested in neoplasia. 4 Renal indications for the preferential use of ACE inhibitors now include not only 'nephro-protection' in type I diabetics with micro-albuminuria with or without raised blood pressure, 5, 6 non-diabetic proteinuria, [7] [8] [9] [10] chronic allograft nephropathy 11, 12 but also control of hypertension, reversal or amelioration of LV hypertrophy (LVH) 13, 14 amelioration of increased large artery stiffness, 13 and post-transplant erythrocytosis. 15 actoid kinin-excess syndromes when used with polyacrilonitrile dialysis membranes. 16 Thus, one could expect great enthusiasm in the nephrological community about the ever-wider use of ACE inhibitors. Better treatment of diabetics and hypertensives must surely equate to fewer cases of end-stage renal failure? 17 After all, in our own dialysis and transplantation patients hypertension is prevalent and difficult to control, LV hypertrophy (LVH) the norm, and the cardiovascular death toll is very alarming. 18 Ex cathedra calls for the more widespread use of ACE inhibitors can be found. 19 More typically though there is much apprehension. Why? Is this parochial arrogance ('only we can use these drugs properly')? The reason for the ambivalence is renal failure-not the interstitial nephritis seen with the huge doses of ACE inhibitors first used in the 1970s, but acute renal failure due to overt, or occult, atherosclerotic renal arterial disease (ARAS). ARAS may account for 15-20% of end-stage renal failure in first-world countries; one-third of patients with peripheral vascular disease, or coronary artery disease, also have significant ARAS. 20 The diagnostic dilemma concerning elderly patients with 'congestive cardiac failure' (treated with diuretics and ACE inhibitors) which is either caused by, or exacerbated by, renal arterial disease ('flash pulmonary oedema') is now more widely appreciated 21, 22 but all too often after an episode of acute renal failure, not before. Even without invoking ARAS, it must also be borne in mind that volume depletion (eg diarrhoea, vomiting, haemorrhage) per se can provoke acute renal failure in a patient whose renin-angiotensin system has been chronically disabled by ACE inhibitors (ACEI). 23, 24 The same strictures apply to angiotensin-antagonists. 25 As the typical 'renal' patient in the 21st century is around 60 years of age, frequently diabetic, with cardiovascular comorbid conditions, it is now more likely than ever that such patients will have been exposed to ACE inhibition at some stage, and that
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A recent study throws these issues into sharp perspective (HOPE: Heart Outcomes Protection Evaluation). Patients greater than 55 years of age with a history of coronary heart disease, stroke, peripheral vascular disease, or diabetes plus at least one other cardiovascular risk factor (hypertension, elevated cholesterol, reduced high-density level (HDL)-cholesterol, cigarette smoking, and microalbuminuria) were randomised to ramipril 10 mg daily vs placebo. 26 Patients with uncontrolled hypertension, or 'overt nephropathy' were excluded. A total of 9297 patients underwent randomisation. Over 90% of these patients had documented or inferred normal LV function. All causes mortality was reduced (relative risk (RR) 0.84 (0.75-0.95, P = 0.006) and cardiovascular mortality/events was also reduced (RR 0.78 (0.70-0.86, P Ͻ 0.001). Withdrawal rates from active therapy were modest, as were side effects. Acute renal failure as a reason for trial withdrawal was not reported. Importantly, the antihypertensive effect of ramipril was modest (4/2 mm Hg placebo-corrected for entry blood pressure), which strongly implicates alternative mechanisms to explain the cardiovascular benefit.
Given the rates of raised cholesterol, blood pressure and glucose intolerance in 'advanced' countries, with their attendant rates of cardiovascular disease, the group of subjects that could theoretically benefit from this ACE inhibitor approach is very large indeed. What can we nephrologists expect to see in the future-more patients suddenly requiring renal dialysis with ACE inhibitor-induced renal failure? More patients surviving cardiac challenges to live long enough for their kidneys slowly then to fail (exactly what is happening to many type II diabetic patients)? Or fewer patients with renal failure, as blood pressure is all the better controlled in a greater number of vulnerable subjects? What should we be doing with ACE inhibitors in our own renal failure patients with ARAS, 27 sharing so many atherosclerotic eligibility risk factors with the 'HOPE' trial subjects, [28] [29] [30] [31] and having amongst the worst prognoses on renal replacement therapy programmes? 27 Specific situations help to clarify responses. First, the diabetic patient with diabetic nephropathy, and with a previous MI and poor LV function, and some renal artery stenosis? The cardiologists and diabetologists would employ ACE inhibition, as would we for the diabetic nephropathy. However the ARAS would most likely preclude the use of ACE inhibitors. Is that always true? If the patient had unilateral mild-to-moderate ARAS then a cautious trial of ACEI should be possible, using plasma creatinine, or glomerular filtration rate (GFR), as a guide to the continuation of therapy.
Another dilemma is a patient with the above, or more, indications for ACEI but a single functional kidney with some ARAS. Here, if the indication for ACEI is strong enough, one could contemplate invasive arterial intervention (with the attendant risk) to open up the artery then more safely allowing sustained ACEI usage. Striking success in controlling blood pressure in 'refractory' ARAS hypertension using a combination of renal arterial patency restoration and angiotensin-antagonism, has recently been reported. 32 Some useful information and guidance can be gleaned from a variety of sources. First, the fact that acute renal failure was not an issue in the HOPE trial subjects over a 5-year period seems reassuring. 26 However, their screening for renal disease-the absence of proteinuria and the reliance only on plasma creatinine lying in a 'normal range'-by no means excludes ARAS. In fact it has emerged that a few patients with renal impairment were included in HOPE. 19 Presumably this means that there were few or no cases of bilateral severe ARAS in the ramipril group, at any stage during the 5 years of the study. Without more information on the rate of progression of subcritical renal arterial lesions in the context of ACEI 33 we cannot be certain how many future cases of acute, or chronic, renal problems will occur with this much wider potential use of these drugs. 34 Second, where ACEI have been deliberately used in ARAS, there has been clear evidence of their superiority as antihypertensive agents. In a study by Tullis et al 35 to examine the still poorly-understood relationship between ARAS and blood pressure control, duplex ultrasonography was used as a noninvasive method for detecting and grading ARAS. The purpose of this study was to characterise the relationship between the degree of ARAS, levels of blood pressure, and control of blood pressure with antihypertensive medication. A cross-sectional analysis was performed on 139 patients with known ARAS. All patients had at least one diseased renal artery by duplex ultrasound. Renal arteries were classified as normal, less than 60% stenosis, or 60% or greater (high-grade) stenosis. Data regarding blood pressure coexisting risk factors, and medications were collected. The extent of ARAS was significantly associated with progressive elevation of the systolic blood pressure, whereas the diastolic component was elevated in the case of unilateral high-grade stenosis: no high-grade stenoses, 153 ± 22/81 ± 10 mm Hg; unilateral high-grade stenosis, 162 ± 22/86 ± 9 mm Hg; and bilateral high-grade stenoses, 174 ± 27/82 ± 9 mm Hg (P = 0.002 systolic; P = 0.02 diastolic). Eighty-two percent of the patients were taking antihypertensive medications. ACEI usage vs non-usage was associated with a significantly lower systolic (157 ± 27 vs 169 ± 22 mm Hg; P = 0.03) and diastolic (79 ± 9 vs 85 ± 9 mm Hg; P = 0.001) blood pressure. The effect of ACEI usage was observed in patients with highgrade ARAS. None of the other classes of antihypertensive medications were associated with significantly lower blood pressure. In patients with ARAS, blood pressure levels were correlated with the sever-ity of renal artery disease. Patients taking ACEIs had significantly lower blood pressures, and the effect of ACEI usage was strongest among patients with unilateral ARAS Third, a recent study by Losito et al 36 from Perugia addressed some of the 'twin-targets', ie 'heart or kidneys' dilemmas. They took 64 patients with diffuse atherosclerotic vascular disease and ARAS. The patients were followed for an average period of 37.3 ± 20.4 months. At the end of the follow-up they found a cumulative survival at 5 years of 60% ± 10. Cerebrovascular and cardiovascular disease were responsible for 92% of deaths. A decrease in creatinine clearance Ͼ10 ml/min at 5 years was found in 65% of patients, three of whom ended in dialysis. Multivariate analysis of predictors of survival showed that treatment with ACEI was significantly associated with a favourable outcome (P = 0.019). Conversely, proteinuria had a negative effect. Renal survival was best predicted by the level of renal function at entry (P = 0.02), and was not influenced by pharmacological treatment.
Last is the valuable account of the prospective use of ACE inhibitors to diagnose ARAS, 37 especially interesting as a reliable, inexpensive way of screening for ARAS is not available. This study examined the consequences of carefully-controlled exposure to ACEI on plasma creatinine in 108 patients at risk for severe bilateral ARAS, and compared the findings with subsequent angiography. ACEI was given for 2 weeks, or, to avoid acute renal failure for 4 days, if plasma creatinine had increased by 20% or more. If after 2 weeks of ACEI plasma creatinine had not increased by у20%, while blood pressure was still elevated, plasma creatinine was remeasured after blood pressure control by addition of diuretics. The severity of renovascular disease (RVD) was scored by the stenosis grade of the better perfused kidney. Fifty-two patients had severe bilateral RVD, defined as у50% stenosis to both kidneys (n = 23) or a solitary functioning kidney (n = 29). Of the others, 21 had less severe bilateral RVD, 20 unilateral RVD, and 15 no apparent RVD. Basal plasma creatinine was higher in severe bilateral RVD (median 170 mol/l, range 85 to 654 mol/l) than in the others (122 mol/l, 62 to 675 mol/l; P Ͻ 0.01), but not discriminative due to a large variability. The increase during ACEI was correlated with the degree of RVD (r = 0.53, P Ͻ 0.001). In 69 patients ACEI caused at least a 20% increase in plasma creatinine, in 26 cases by 4 days, in 31 after 2 weeks, and in 12 only after blood pressure control by diuretics. Among these were all 52 patients with severe bilateral RVD, 15 of the 41 patients with lesser forms of RVD, and two with normal renal arteries. Thus, in this selected population the criterion of у20% rise in plasma creatinine upon ACEI was 100% sensitive to detect severe bilateral RVD, while its specificity was 70%. No case of acute renal failure was encountered, and plasma creatinine always recovered after stopping ACEI. In conclusion, controlled exposure
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This work implies the need for monitoring of renal function in patients on ACEI. However a recent community-based general practitioner (GP) census revealed that this was rarely practiced. 38 From 277 UK GPs who completed the survey 85% (235) checked renal function before but only 93 (34%) after the start of treatment, while 42 (15%) never checked renal function. ACE inhibitors were prescribed for 162 patients from a total of 3625 aged Ͼ35 years (mean age 66.4 (s.d. 15.9) years). Monitoring of renal function occurred before treatment in 55 (45%) and after start of treatment in 35 (29%) of the 122 patients treated in general practice. ACE inhibitors could be causally implicated in nine (7%) of 135 admissions for uraemia (mean age 74.2 (7.2) vs 62.1 (2.1) years; P Ͻ0.01). Three patients had RVD and six had congestive cardiac failure with another intercurrent illness. Renal function had not been checked in any patient after the start of treatment; mean duration of illness before admission was 10.5 (3.2) days. Mean length of hospital stay was 20.9 (10.4) days; there were eight survivors.
Thus it may well be that there is a renal therapeutic paradox in ARAS. Although it is clear that the degree of arterial stenosis in ARAS does worsen with time, though progression to occlusion is unusual, 39 the renal functional decline seen in ARAS 33 in reality owes more to chronic ischaemia or 'atherosclerotic nephropathy', [40] [41] [42] which is a compô te of scarring, micro-embolisation and pure hypertension, than to any effect of worsening degree of arterial stenosis. Scoble's work has elegantly shown that the degree of stenosis in a renal artery and that kidney's individual renal GFR are not related. 43, 44 This 'atherosclerotic nephropathy' lesion is likely to benefit most from ACEI (and quite likely from other medical interventions), as evidenced by significant falls in blood pressure on ACEI. 32, 35 It is also likely that the same patients' hearts and brains will also substantially benefit from ACEI too. However, if the ARAS lesion is haemodynamically very significant (Ͼ80% stenosis), renal perfusion can be the more easily prejudiced by the use of ACEI. Unilateral ARAS can easily fail to be recognised; 24 though if the contralateral kidney functions well, while the affected kidney is small and functionally insignificant, the resulting ACEIinduced pharamacological unilateral nephrectomy is likely to be a good outcome. Here, the use of splitfunction isotopic renography, a cheap and reproducible investigation giving total as well as true lateralised individual renal GFR may prove valuable for monitoring the effect of ACEI therapy in selected patients at highest risk of ARAS. 44, 45 There needs to be a prospective trial of the use of ACEI vs 'best blood pressure treatment' eg with alpha-and beta-blockers in these ARAS patients, with patient, and renal, survivals as primary endpoints.
If the ever-wider use of aspirin, lipid-lowering therapy and ACEI is a successful strategy at halting major progression of atherosclerotic lesions in all vascular beds there may not be a major 'pay-back' for the extensive use of these compounds in a highrisk population over a sustained period. 46 I suspect that we will see a greater proportion of elderly vasculopaths in the years ahead with acute renal failure in the context of ACEI. This is the probable price that has to be paid for the benefit seen in other patients who avoid major cardiovascular complications. I also suspect that before long few patients with any type of renal problem (save overt bilateral severe ARAS) will escape ACE inhibition.
ACEI, if they are to be used in the community (which they must in the UK to reach the patients who may benefit most), must be used responsiblythat means plasma electrolyte estimation and urinalysis before starting treatment, investigation of macro-proteinuria or abnormal renal function, referral to nephrologists of patients with unexplained renal impairment, and re-checking blood and urine tests soon after starting ACEI, and periodically thereafter. New guidelines for the ever wider use of ACEI are overdue
